# Motilal Oswal initiates coverage on Molbio Diagnostics with buy rating 2026-10-05T08:31:40+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Motilal Oswal Financial Services has initiated coverage on Molbio Diagnostics Ltd with a 'buy' rating and a target price of ₹1,800, implying a 19% upside from its closing price of ₹1,513.10 on 1 October. In a bull-case scenario, the brokerage sees a target of ₹2,575, implying a 70% upside from the close on 9 October. Molbio Diagnostics listed on 17 August at ₹980, a 21.44% premium to the IPO price of ₹807. The stock had already doubled from its issue price within 21 days of listing, reaching a post-listing high of ₹1,686. Motilal Oswal expects the company's revenue to grow at a 23% CAGR over FY26-29, driven by higher utilisation of its TrueNat platform and expansion into digital pathology and imaging. All three analysts covering the stock have a 'buy' rating. Motilal Oswal's target is the highest among brokerages, with Jefferies at ₹1,600 and IIFL at ₹1,550. The brokerage identified dependence on government orders and elevated working capital as key risks. ## Indian Opinion Analysis Motilal Oswal's bull case of ₹2,575 is based on aggressive assumptions: 26% revenue CAGR, 1,465 basis points of margin expansion and a 58% earnings CAGR over FY26-29. The brokerage applies a 50-times forward P/E multiple, compared with 45 times in its base case. The key variable is whether the TrueNat platform can sustain high utilisation through new indications such as HPV testing, and whether early-stage businesses like OptraSCAN's US commercialisation gain traction. The stock's 24% rally in three sessions before this note suggests the market had already priced in some optimism. ## Coverage - cnbctv18.com Reports brokerage initiation with bull and base case targets, analyst consensus and risks without editorial slant This brief was synthesised by AI from the source linked above. Tags: IPO, Molbio Diagnostics, Motilal Oswal, Truenat Canonical: https://indianopinion.org/motilal-oswal-initiates-coverage-on-molbio-diagnostics-with-buy-rating/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/motilal-oswal-initiates-coverage-on-molbio-diagnostics-with-buy-rating/#story-in-brief How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/